Literature DB >> 18482018

Angioedema after ovine hyaluronidase injection for treating hyaluronic acid overcorrection.

Pierre Andre1, Marie Laure Fléchet.   

Abstract

BACKGROUND: Hyaluronic acid injections are becoming popular in aesthetic dermatology, and, sometimes, misplacements and very rarely adverse events have been reported. Hyaluronidase, an enzyme that hydrolyzes hyaluronic acid, is used to treat overcorrection or granulomatous reactions. Allergic reactions are well known except for how frequent they occur.
OBJECTIVE: This paper aims to confirm the efficacy of hyaluronidase injections to dissolve hyaluronic acid, but insists on the risk of hypersensitivity with animal-derived products.
METHODS: A case of angioedema due to ovine hyaluronidase is reported, and treatment is discussed.
CONCLUSION: Hyaluronidase is highly effective, but skin test must be done before injection to avoid risk of angioedema and/or Quincke's edema.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482018     DOI: 10.1111/j.1473-2165.2008.00377.x

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  4 in total

1.  Severe Acute Local Reactions to a Hyaluronic Acid-derived Dermal Filler.

Authors:  Susan Van Dyke; Geoffrey P Hays; Anthony E Caglia; Michael Caglia
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

2.  This month's guideline: The Use of Hyaluronidase in Aesthetic Practice (v2.4).

Authors:  Martyn King; Cormac Convery; Emma Davies
Journal:  J Clin Aesthet Dermatol       Date:  2018-06-01

3.  Acute urticaria caused by the injection of goat-derived hyaluronidase.

Authors:  Joo-Hee Kim; Gil-Soon Choi; Young-Min Ye; Dong-Ho Nahm; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2009-09-25       Impact factor: 5.764

4.  Treatment of late bacterial infections resulting from soft-tissue filler injections.

Authors:  Wojciech Marusza; Romuald Olszanski; Janusz Sierdzinski; Tomasz Ostrowski; Kamila Szyller; Grazyna Mlynarczyk; Irina Netsvyetayeva
Journal:  Infect Drug Resist       Date:  2019-02-20       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.